Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology & Hematology

How to make non-immunogenic cancers sensitive to checkpoint inhibitors

We have been following the results of the checkpoint inhibitors for several years now, first with ipilimumab (Yervoy) and lately with anti-PD1 and PD-L1 inhibitors such as nivolumab, pembrolizumab and MPDL3280A. Irrespective of the antibody used, the best results we’ve seen have in melanoma, lung and bladder, but some tumour types such as colon and prostate cancers have barely been responsive at all.

Leave a comment
error: Content is protected !!